间充质干细胞移植治疗终末期肝病前后血清甲胎球蛋白的变化  

The change of serum α-fetoprotein during mesenchymal stem cell transplantation in the treatment of end-stage liver disease

作　　者：陈建华[1] 徐玉琴 杨晋辉[3] 张军 

机构地区：[1]川北医学院药学院药理教研室,四川南充637000 [2]哈尔滨211医院感染科,黑龙江哈尔滨市150030 [3]昆明医学院第二附属医院消化内科,云南昆明650000 [4]深圳市北科生物科技有限公司生命健康部,广东深圳518057

出　　处：《分子诊断与治疗杂志》2015年第2期110-113,共4页Journal of Molecular Diagnostics and Therapy

基　　金：间充质干细胞临床应用高技术产业化(2011GH021787)

摘　　要：目的探讨间充质干细胞(mesenchymal stem cell,MSC)移植治疗终末期肝病甲胎球蛋白(α-fetoprotein,AFP)的变化,观察病人肝功能有无改善。方法 MSC移植治疗73例终末期肝病患者,其中包括失代偿期肝硬化患者45例,慢性重症肝炎5例,监测疗前和疗后1周、疗后1个月、2个月AFP及肝功能变化。结果疗后1周AFP较疗前明显升高,其后降低,2个月至疗前水平,差别有统计学差异(P<0.05)。白蛋白(serum albumin,ALB)疗后1月、2月与疗前相比,差别有统计学意义(P<0.05)。胆碱酯酶疗后2月较疗前明显升高,差别有统计学意义(P<0.05)。所有接受干细胞移植的患者观察过程中未出现肝脏及其他器官肿瘤。结论 MSC移植治疗终末期肝病患者安全有效。Objective To explore the changes of α-fetoprotein（AFP） in end-stage liver disease after mesenchymal stem cell （MSC） transplantation and observe whether patient＇s liver function had been improved. Methods 73 patients with end stage liver disease were transplanted with MSC, including 45 decompensated hepatic cirrhosis and 5 chronic severe hepatitis patients. The serum levels of AFP, liver function were examined 1 week before treatment and 1 week, 1 month, and 2 months after treatment. Results The level of AFP increased at 1 week after treatment, and returned to normal level 2 months later. There was statistical difference between before treatment and after treatment （P 〈 0.05）. The results revealed a statistically significant difference between before treatment and after 1, 2 months treatment in serum albumin（ALB）（P 〈 0.05）. Likewise, there was significant difference between before treatment and after 2 months treatment in Cholinesterase （P 〈 0.05）. No person suffered from any other tumor under thorough observation. Conclusion MSC transplantation is a safe and effective in the treatment of end-stage liver disease.

关 键 词：间充质干细胞(MSC) 移植 甲胎球蛋白(AFP) 

分 类 号：R575.3[医药卫生—消化系统]